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Interest in the biological applications of oleochemicals has resulted in the development of new heterocyclic compounds 
from the fatty acids which are renewable raw materials. In the present study the synthesis of hybrid compounds by involving 
fatty acids, indole-3-acetic acid (heteryl) and trimethoxy benzoic acid (aryl) to derive 2, 5-substituted 1,3,4-oxadiazole 
moiety using molecular hybridization approach has been carried out. A series of novel 2-((1H-indol-3-yl) methyl)-5-alkyl-
1,3,4-oxadiazoles 4a-j and 2-alkyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole 8a-j analogues have been synthesized and 
evaluated for their cytotoxicity against A549, MCF-7 and HeLa cell lines. Almost all the tested compounds reveal 
cytotoxicity against all the cell lines, especially 2-((1H-indol-3-yl) methyl)-5-alkyl-1,3,4-oxadiazoles based compounds (4c, 
4d, 4e) which display potent inhibitory activity with IC50 values ranging between 8.26 to 11.36 µM. 
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Cancer remains one of the most life-threatening 
diseases worldwide. This is one class of disease 
characterized by an abnormal cell growth and 
proliferation with the potential to infect surrounding 
tissues and metastasize to other tissues in the body. 
Most of the world's population at risk represents a 
major public health problem due to its morbidity and 
mortality1-5. Therefore, continuous efforts are needed 
to develop novel compounds with improved 
selectivity and activity by chemical modifications. 
 
It is well-known that heterocyclic chemistry is one 
of the most valuable sources of new compounds with 
diverse biological activity. In this regard, nitrogen and 
oxygen containing five membered heterocyclic 
compounds have received considerable attention due 
to their wide range of biological and pharmacological 
activities. Among the family of heterocyclic 
compounds, the five membered oxadiazoles and their 
derivatives provide a valuable scaffold in medicinal 
chemistry. In this connection, 1,3,4-Oxadiazoles are 
of paramount interest of the synthetic and medicinal 
chemists because they are the important precursors for 
various heterocycles and also a privileged structural 
component in a variety of bioactive molecules. 1,3,4-
Oxadiazole motif makes up the core structure of 
numerous biologically active compounds such as 
anticancer6, antimicrobial7, antineoplastic8, 
antifungal9-10, antibacterial activities 11. In addition, 
many fatty acids12 and fatty amides 13 are known to 
exhibit antimicrobial and cytotoxic activities. Long 
alkyl/alkenyl chains exhibited antimicrobial activity 
and some fatty acid derivatives were also known to 
possess antitumor and anti-depressant activities14-16. 
 
Meanwhile, methoxy groups on aryl systems have 
been broadly investigated for their biological 
effects17. These groups are important in cytotoxic and 
microtubule-binding agents used for cancer 
chemotherapy18 - 19. Recent studies on combretastatin 
A-4, which is an antitumour drug from the 
combretastatin group 20, have shown that the 3,4,5-
trimethoxy phenyl groups are important for its 
antitumour activity21, 22. Moreover, recently various 
trimethoxy chalcones and their analogues have 
antioxidant activities23. The incorporation of 
trimethoxyphenyl moiety in organic compounds has 
attracted considerable attention due to its naturally 
derived characterization and wide prevalence in 
pesticides and medicinal compounds24 - 26. In addition 
to that indole nucleus is a privileged scaffold in 
natural and synthetic compounds with a wide range of 
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biological activities 27. Indole is a core structural unit 
of many natural products and is widely used in 
agricultural and medicinal chemistry. Compounds 
containing an indole nucleus display a wide range of 
biological activities, such as anticancer, antidiabetic, 
antirheumatoidal, antioxidant and antiviral 
properties28. In that indole-3-acetic acid is a key plant 
growth hormone29, tryptophan, an essential amino 
acid, participates in various biological processes 30  
and Indomethacin is a nonsteroidal anti-inflammatory 
drug 31.  
 
Results and Discussion 
A series of some 2-((1H-indol-3-yl) methyl)-5-
alkyl-1,3,4-oxadiazoles (4a-4j) and 2-alkyl-5-(3,4,5-
trimethoxyphenyl)-1,3,4-oxadiazole (8a–8j) 
derivatives were synthesized and as outlined in 
Scheme I and Scheme II. Aryl and heteroyl acid 
hydrazides (3, 7) were synthesized by the reaction of 
85% hydrazine hydrate and compounds 2, 6 were 
derived from corresponding acids (1, 5), in ethanol 
under reflux conditions. Acid hydrazides (3, 7) 
derived from corresponding acids (1, 5) were cyclized 
with fatty acids in presence of phosphorus 
oxychloride to afford 2,5-disubstituted-1,3,4-
oxadiazole derivatives (4a-4j, 8a–8j). All the 
compounds were characterized by spectroscopic (IR, 
1H NMR, 13C NMR and mass) studies. 
The structures of the newly synthesized compounds 
(4a-4j) and (8a–8j) were confirmed by spectral data 
(1H NMR, 13C NMR, IR, and ESI-MS). All the 
spectral data of the synthesized compounds were in 
full agreement with the proposed structures and also 
discussed for a representative compounds such as (2-
((1H-indol-3-yl) methyl)-5-propyl-1,3,4-oxadiazole) 
(4a), 2-propyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-
oxadiazole (8a). For 4a derivative, aromatic protons 
appeared as three distinct regions at 7.62 (d, J = 
7.9Hz, 1H, Ar-H), 7.36 (d, J = 7.9Hz, 1H, Ar-H), 
7.11-7.22 (m, 3H, Ar-H), where as CH2 protons 
observed between indole ring and oxadiazole ring 
resonated as singlet at 4.32 (s, 2H, CH2), CH2 protons 
containing alkyl chain adjacent to oxadiazole ring 
resonated as triplet at 2.72-2.76 (t, J = 7.5Hz, 2H, 
CH2) and remaining aliphatic alkyl chain CH2 protons 
appeared at 1.73-1.79 (m, 2H, CH2). Further terminal 
methyl group protons observed as a triplet in the 
region 0.95 – 0.98 (t, J = 6.7Hz, 3H, CH3) and from 
the 13C NMR, peaks at 166.8 and 165.5 were 
represents oxadiazole moiety. Further, the structure of 
4a was also confirmed by mass spectrum showed a 
molecular ion peak at m/z 264 [M+Na]+. The 
observed molecular mass is in agreement with the 
assigned molecular formula. Finally HRMS spectrum 
of this compound showed a molecular ion peak m/z 
[M+H+]: calc for C14H16ON3 is 242.12879 found 
242.12825 (C14H16ON3) in consistent with its 
molecular formula. 
Similarly for 8a derivative, aromatic protons 
appeared as a singlet at δ 7.26 (s, 2H, Ar-H), where as 
OCH3 protons of trimethoxy phenyl ring resonated as 
a singlet at 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 
CH2 protons containing alkyl chain adjacent to 
oxadiazole ring appeared as a triplet at 2.89-2.92 (t, J 
 
 
Scheme I — Reagent and conditions: (a) EtOH, H2SO4 reflux, 12 h, (b) hydrazine hydrate, EtOH reflux, 10 h, (c) R-COOH, POCl3, 
reflux, 6 h 
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= 7.4Hz, 2H, CH2) and remaining aliphatic alkyl 
chain CH2 protons observed at 1.86-1.92 (m, 2H, 
CH2). The terminal methyl group protons appeared as 
a triplet in the region 1.05-1.09 (t, J = 6.8Hz, 3H, 
CH3) and from the 13C NMR, peaks at 166.4 and 
164.2 were due to oxadiazole moiety formation. 
Further, the structure of 8a was also confirmed by its 
mass spectrum showed a molecular ion peak at m/z 
301 [M+Na]+. The observed molecular mass is in 
agreement with the assigned molecular formula. 
Finally HRMS spectrum of this compound showed 
molecular ion peak m/z [M+H+]: calc for C14H19O4N2 
is 279.13393 found 279.13324 (C14H19O4N2). 
 
Biology 
The cytotoxicity of the newly synthesized 
compounds (4a-4j, 8a–8j) were tested using MTT 
assay against A549 (human lung cancer cell), MCF-7 
(human breast cancer cell), HeLa (human 
adenocarcinoma cells) and one normal cell line i.e. 
HEK 293. The selectivity index (SI) was also 
determined using the following formula: SI = IC50 of 
pure compound in a normal cell line / IC50 of the same 
pure compound in cancer cell line, where IC50 is the 
concentration required to inhibit 50% of the cell 
population. High SI value (>2) of a compound gives a 
selective toxicity towards cancer cells, while the 
compound with SI value <2 is considered to provide 
general toxicity in which it also can cause cytotoxicity 
in normal cells32. Inhibition of cell proliferation by 
these active compounds at various concentrations 
were measured, and their IC50 (the concentration that 
caused 50% cell proliferation inhibition) values were 
calculated and summarized in Table I. Doxorubicin 
was used as a positive control. The obtained data 
revealed that most of the synthesized compounds 
showed good to promising cytotoxicity on all the 
tested cell lines (Table I). Among the tested 
compounds, 4c, 4d and 4e showed promising activity 
against all the cell lines with IC50 values ranging 
between 8.26 to 11.36 µM, and these results are in good 
agreement with the previous results obtained for 
heterocyclic based fatty acid compounds 33, 34. While the 
remaining compounds showed moderate activity.  
Further, all the tested compounds showed poor 
cytotoxicity on HEK293 (normal human embryonic 
kidney cells). Based on the cytotoxicity results against 
various cell lines, some information on the structure-
activity relationship can be derived. Heteryl and fatty 
acid group substitution on oxadiazole ring favours good 
activity as compared to aryl and fatty acid group 
substitution on the oxadiazole ring. Also, the 
introduction of fatty alkyl chain in both the cases 
exhibited cytotoxicity. It was observed that the major 
difference between these molecules considering the 
variation in the cytotoxicity is due to the variation in 
carbon chain length and the substitution of heteryl and 
aryl groups. 
 
Experimental Section 
 
Materials and methods 
All the chemicals used in this study were obtained 
from different commercial sources and were used 
without any further purification. Reactions were 
 
 
Scheme II — Reagent and conditions: (a). EtOH, H2SO4 reflux, 12 h, (b). hydrazine hydrate, EtOH reflux, 10 h, (c). R-COOH, POCl3, 
reflux, 6 h 
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monitored on micro TLC with UV detection. Final 
purification was carried out using silica gel 60-120 
mesh (Rankem). All 1H and 13C NMR spectra were 
recorded on AVANCE (300 and 500 MHz for 1H 
NMR and 75 MHz for 13CNMR). Chemical shifts are 
reported in ppm with reference to internal standard 
TMS. Molecular weights of unknown compounds 
were identified by ESI-MS and HRMS (Electron 
spray ionization technique). IR spectra were recorded 
in chloroform on a Perkin-Elmer FT-IR spectrum BX.  
 
Synthesis of ethyl 2-(1H-indol-3-yl) acetate, 2 
The ester was prepared by refluxing 2-(1H-indol-3-
yl) acetic acid (5 g, 1 mmol) in excess of absolute 
ethanol (50 mL) in the presence of few drops of conc. 
sulphuric acid for 12 h and the progress of reaction was 
monitored by TLC. After 12 h reaction time, the 
solvent was evaporated under reduced pressure, water 
was added and the product was extracted with ethyl 
acetate and dried over anhydrous sodium sulphate. The 
crude product was purified by using column 
chromatography to afford the title compound in 86% 
yield. 1H NMR (300 MHz, CDCl3): δ 8.11 (Broad- 
singlet, 1H, NH), 7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.36 
(d, J = 7.9Hz, 1H, Ar-H), 7.11-7.22 (m, 3H, Ar-H), 
4.13-4.19 (m, 2H, CH2), 1.23-1.27 (t, J = 7.1Hz, 3H, 
CH3); MS (ESI, m/z) [M+Na]+ 226. 
 
Synthesis of 2-(1H-indol-3-yl) acetohydrazide, 3 
A mixture of ethyl 2-(1H-indol-3-yl) acetate (2 g, 1 
mmol), hydrazine hydrate (6 mL, 15 mmol) and 20 mL 
of ethanol was refluxed on an oil bath for 10 h and the 
progress of reaction was monitored by TLC. After 10 h 
reaction time, the solvent was evaporated under reduced 
pressure and the concentrated solution was quenched to 
ice cold water. The solid separated was filtered, washed 
and dried. The crude product was purified by 
recrystalization from ethanol which afforded the title 
compound in 74% yield. 1H NMR (300 MHz, CDCl3): δ 
8.11 (Broad- singlet, 1H, NH), 7.62 (d, J = 7.9Hz, 1H, 
Ar-H), δ 7.53 (Broad-singlet, 1H, NH), 7.36 (d, J = 
7.9Hz, 1H, Ar-H), 7.11-7.22 (m, 3H, Ar-H), 4.13-4.19 
(m, 2H, CH2), 4.12 (Broad-singlet, 2H, NH2),1.23-1.27 
(t, 3H, CH3); MS (ESI, m/z) [M+H]+ 190. 
 
General procedure for the synthesis of target 
compounds, 4a-j 
A mixture of 2-(1H-indol-3-yl) acetohydrazide (3) 
(1mmol), fatty acids (1mmoL) and phosphorous 
Table I — Results of cytotoxicity of the synthesized compounds 
 IC50 values (µM) 
A549 SI† MCF 7 SI† HeLa SI† HEK293 
4a 18.36 ± 0.03 5.15 16.79 ± 0.92 5.63 20.18 ± 0.06 4.68 94.56 ± 0.12 
4b 19.20 ± 0.96 4.90 18.87 ± 0.63 4.99 20.31 ±0.32 4.63 94.23 ± 0.52 
4c 9.05 ± 0.59 9.86 9.50 ± 0.86 9.39 10.26 ± 0.98 8.69 89.24 ± 0.08 
4d 8.26 ± 0.49 10.84 10.18 ± 0.36 8.80 10.26 ± 0.56 8.73 89.61 ± 0.46 
4e 9.31 ± 0.97 9.25 9.24 ± 0.84 9.33 11.36 ± 0.06 7.58 86.21 ± 0.31 
4f 25.13 ± 0.02 3.94 20.92 ± 0.98 4.74 18.26 ± 0.26 5.43 99.23 ± 0.16 
4g 23.06 ± 0.09 4.20 19.21 ± 0.92 5.05 20.23 ± 0.58 4.79 97.08 ± 0.89 
4h 31.03 ± 0.25 2.72 29.78 ± 0.32 2.83 30.20 ± 0.36 2.80 84.56 ± 0.93 
4i 63.06 ± 0.46 1.40 61.79 ± 0.69 1.43 62.31 ± 0.89 1.41 88.46 ± 0.13 
4j 17.65 ± 0.96 4.73 13.85 ± 0.36 6.03 19.26 ± 0.26 4.33 83.56 ± 0.59 
8a 19.93 ± 0.42 4.82 17.67 ± 0.06 5.44 20.01 ± 0.12 4.81 96.26 ± 0.92 
8b 20.63 ± 0.96 4.33 18.60 ± 0.93 4.80 21.97 ± 0.86 4.06 89.36 ± 0.36 
8c 22.30 ± 0.45 4.36 19.22 ± 0.23 5.06 18.10 ± 0.23 5.37 97.26 ± 0.46 
8d 21.49 ± 0.32 3.54 19.77 ± 0.96 3.85 18.03 ± 0.29 4.22 76.26 ± 0.76 
8e 26.16 ± 0.51 3.40 24.51 ± 0.33 3.63 27.06 ± 0.31 3.29 89.16 ± 0.89 
8f 35.18 ± 0.51 2.73 33.57 ± 0.32 2.86 39.98 ± 0.66 2.40 96.26 ± 0.21 
8g 17.69 ± 0.18 4.94 18.22 ± 1.93 4.80 16.96 ± 0.69 5.16 87.56 ± 0.26 
8h 16.34 ± 0.84 6.06 15.74 ± 0.95 6.29 18.18 ± 0.98 5.44 99.03 ± 0.79 
8i 19.76 ± 0.72 3.87 16.50 ± 0.36 4.64 23.60 ± 0.12 3.24 76.56 ± 0.25 
8j 17.94 ± 0.65 4.88 16.75 ± 0.09 5.23 21.09 ± 0.35 4.15 87.65 ± 0.13 
Doxorubicin 2.10 ± 0.09 37.26 3.12 ± 0.12 25.08 1.78 ± 0.24 43.96 78.26 ± 0.89 
IC50 is the concentration required to inhibit 50% of the cell population; A549: human alveolar adenocarcinoma epithelial cells (ATCC No. 
CCL-185), MCF-7: human breast adenocarcinoma cells (ATCC No. HTB-22), HeLa: human cervical cancer cell line (ATCC No. CCL-2);
HEK293: normal human embryonic kidney cells (ATCC No. CRL-1573) 
 †Selectivity index (SI) = IC50 of pure compound in a normal cell line / IC50 of the same pure compound in cancer cell line, where IC50 is 
the concentration required to inhibit 50% of the cell population 
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oxychloride (2.5mL) was refluxed for 6 h. The excess 
solvent was distilled off under reduced pressure and 
the residue was quenched with ice cold water and the 
product was extracted with ethyl acetate and dried 
over anhydrous sodium sulphate. The crude product 
was purified by using column chromatography to 
afford the title compounds.  
 
2-((1H-Indol-3-yl) methyl)-5-propyl-1,3,4-oxadiazole, 
4a 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 43% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.25 (s, 1H, NH), 
7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.36 (d, J = 7.9Hz, 1H, Ar-
H), 7.11-7.22 (m, 3H, Ar-H), 4.32 (s, 2H, CH2), 2.72-2.76 
(t, J = 7.5Hz, 2H, CH2), 1.73-1.79 (m, 2H, CH2), 0.95 – 
0.98 (t, J = 6.7Hz, 3H, CH3); 13C NMR (75 MHz, 
CDCl3): δ 166.8, 165.5, 135.8, 126.4, 122.8, 122.0, 119.4, 
118.2, 111.0, 107.9, 26.8, 21.8, 19.5, 13.25; IR (CHCl3 
νmax cm
-1): 3441, 3015, 2936, 2872, 1574, 1498, 1419, 
1217, 1130, 1002, 755, 666; MS (ESI, m/z) [M+Na]+ 264; 
HR-MS (ESI) m/z [M+H+]: calc for C14H16ON3 is 
242.12879 found 242.12825 (C14H16ON3).  
 
2-((1H-Indol-3-yl) methyl)-5-pentyl-1,3,4-oxadiazole, 
4b 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 48% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.30 (s, 1H, NH), 
7.63 (d, J = 7.9Hz, 1H, Ar-H), 7.37 (d, J = 7.9Hz, 1H, 
Ar-H), 7.11-7.22 (m, 3H, Ar-H), 4.31 (s, 2H, CH2), 
2.73-2.77 (t, J = 7.5Hz, 2H, CH2), 1.69-1.75 (m, 2H, 
CH2), 1.28-1.33 (m, 4H, (-CH2-)2), 0.84 – 0.87 (t, J = 
6.7Hz, 3H, CH3); 13C NMR (75 MHz, CDCl3): δ 167.6, 
166.0, 136.4, 127.0, 123.2, 122.7, 120.1, 118.9, 111.5, 
108.7, 31.3, 26.3, 25.5, 22.4, 14.0; IR (CHCl3 νmax cm-
1): 3442, 3015, 2960, 2937, 1574, 1499, 1464, 1419, 
1217, 1130, 1002, 755, 666; MS (ESI, m/z) [M+Na]+ 
292; HR-MS (ESI) m/z [M+H+]: calc for C16 H20 O N3 
is 270.16009 found 270.15958 (C16 H20 O N3). 
 
2-((1H-Indol-3-yl) methyl)-5-heptyl-1,3,4-oxadiazole, 
4c 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 50% yield as a liquid. 
1H NMR (300 MHz, CDCl3): δ 8.22 (s, 1H, NH), 7.62 
(d, J = 7.9Hz, 1H, Ar-H), 7.36 (d, J = 7.9Hz, 1H, Ar-H), 
7.11-7.23 (m, 3H, Ar-H), 4.32 (s, 2H, CH2), 2.73-2.77  
(t, J = 7.5Hz, 2H, CH2), 1.68-1.75 (m, 2H, CH2), 1.21-
1.33 (m, 8H, (-CH2-)4), 0.84 – 0.88 (t, J = 6.7Hz, 3H, 
CH3); 13C NMR (75 MHz, CDCl3): δ 167.6, 166.0, 
136.4, 127.0, 123.4, 122.5, 120.0, 118.8, 111.6, 108.4, 
31.8, 29.1, 26.6, 25.5, 22.8, 22.3, 14.3; IR (CHCl3 νmax 
cm-1): 3441, 3015, 2960, 2937, 1574, 1499, 1464, 1419, 
1217, 1130, 1002, 755, 666; MS (ESI, m/z) [M+H]+ 298; 
HR-MS (ESI) m/z [M+Na+]: calc for C18H23ON3Na is 
320.17333 found 320.17257 (C18H23ON3Na). 
 
2-((1H-Indol-3-yl) methyl)-5-nonyl-1,3,4-
oxadiazole, 4d 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 56% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.17 (s, 1H, 
NH), 7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.37 (d, J = 
7.9Hz, 1H, Ar-H), 7.12-7.24 (m, 3H, Ar-H), 4.32 (s, 
2H, CH2), 2.73-2.77 (t, J = 7.5Hz, 2H, CH2), 1.68-
1.75 (m, 2H, CH2), 1.24-1.31 (m, 12H, (-CH2-)6), 0.85 
– 0.89 (t, J = 6.7Hz, 3H, CH3); 13C NMR (75 MHz, 
CDCl3): δ 167.6, 166.0, 136.4, 127.0, 123.4, 122.6, 
120.0, 118.8, 111.6, 108.5, 32.0, 29.2, 26.6, 25.5, 
22.9, 22.3, 14.3; IR (CHCl3 νmax cm-1): 3442, 3015, 
2960, 2937, 1574, 1499, 1464, 1419, 1217, 1130, 
1002, 755, 666; MS (ESI, m/z) [M+H]+ 326; HR-MS 
(ESI) m/z [M+H+]: calc for C20H28ON3 is 326.22269 
found 326.22208(C20H28ON3). 
 
2-((1H-Indol-3-yl) methyl)-5-(dec-9-en-1-yl)-1,3,4-
oxadiazole, 4e 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 58% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.15 (s, 1H, 
NH), 7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.36 (d, J = 
7.9Hz, 1H, Ar-H), 7.11-7.23 (m, 3H, Ar-H), 5.76-5.84 
(m, 1H, CH2-CH=CH2), 4.91-5.00 (m, 2H, CH2-
CH=CH2), 4.32 (s, 2H, CH2), 2.73-2.76 (t, J = 7.5Hz, 
2H, CH2), 1.98-2.04 (m, 2H, CH2), 1.68-1.74 (m, 2H, 
CH2), 1.25-1.35 (m, 10H, (-CH2-)5); 13C NMR (75 
MHz, CDCl3): δ 167.2, 165.7, 136.1, 131.4, 126.7, 
124.6, 123.0, 122.3, 119.8, 118.6, 114.1, 111.2, 108.4, 
32.4, 29.4, 28.8, 26.3, 25.2, 22.0, 17.8, 13.9; IR (KBr
 
νmax cm
-1): 3297, 2925, 2850, 1732, 1597, 1567, 1461, 
1165, 1102, 966, 741; MS (ESI, m/z) [M+H]+ 338; 
HR-MS (ESI) m/z [M+H+]: calc for C21H28ON3 is 
338.22269 found 338.22207 (C21H28ON3). 
 
2-((1H-Indol-3-yl) methyl)-5-undecyl-1,3,4-
oxadiazole, 4f 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 48% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.23 (s, 1H, 
NH), 7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.36 (d, J = 
7.9Hz, 1H, Ar-H), 7.12-7.22 (m, 3H, Ar-H), 4.31  
(s, 2H, CH2), 2.73-2.76 (t, J = 7.5Hz, 2H, CH2),  
1.68-1.74 (t, J =7.4Hz, 2H, CH2), 1.23-1.32 (m, 16H,  
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(-CH2-)8), 0.86 – 0.89 (t, J = 6.7Hz, 3H, CH3); 13C 
NMR (75 MHz, CDCl3): δ 166.0, 167.6, 136.4, 127.0, 
123.3, 122.6, 120.1, 118.9, 111.5, 108.6, 32.2, 29.9, 
26.6, 25.6, 22.9, 22.4, 14.3; IR (CHCl3 νmax cm-1): 
3441, 3015, 2960, 2937, 1574, 1499, 1464, 1419, 
1217, 1130, 1002, 755, 666; MS (ESI, m/z) [M+H]+ 
354; HR-MS (ESI) m/z [M+H+]: calc for C22H32ON3 
is 354.25399 found 354.25335 (C22H32ON3). 
 
2-((1H-Indol-3-yl) methyl)-5-tridecyl-1,3,4-
oxadiazole, 4g 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 51% yield as a 
liquid. 1H NMR (300 MHz, CDCl3): δ 8.21 (s, 1H, 
NH), 7.64 (d, J = 7.9Hz, 1H, Ar-H), 7.36 (d, J = 
7.9Hz, 1H, Ar-H), 7.12-7.21 (m, 3H, Ar-H), 4.32 (s, 
2H, CH2), 2.73-2.77 (t, J = 7.5Hz, 2H, CH2), 1.68-
1.75 (t, J =7.4Hz, 2H, CH2), 1.23-1.31 (m, 20H, (-
CH2-)10), 0.84 – 0.88 (t, J = 6.7Hz, 3H, CH3); 13C 
NMR (75 MHz, CDCl3): δ 167.0, 165.4, 135.8, 126.3, 
122.7, 121.9, 119.4, 118.2, 110.9, 107.7, 31.5, 29.2, 
26.0, 24.9, 22.3, 21.7, 13.7; IR (CHCl3 νmax cm-1): 
3442, 3015, 2960, 2937, 1574, 1499, 1464, 1419, 
1217, 1130, 1002, 755, 666; MS (ESI, m/z) [M+H]+ 
382; HR-MS (ESI) m/z [M+H+]: calc for C24H36ON3 
is 382.28529 found 382.28515 (C24H36ON3). 
 
2-((1H-Indol-3-yl) methyl)-5-pentadecyl-1,3,4-
oxadiazole, 4h 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 48% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.14 (s, 1H, 
NH), 7.63 (d, J = 7.9Hz, 1H, Ar-H), 7.37 (d,  
J = 7.9Hz, 1H, Ar-H), 7.12-7.24 (m, 3H, Ar-H), 4.32  
(s, 2H, CH2), 2.73-2.77 (t, J = 7.5Hz, 2H, CH2), 1.68-
1.75 (t, J =7.4Hz, 2H, CH2), 1.23-1.25 (m, 24H,  
(-CH2-)12), 0.86 – 0.89 (t, J = 6.7Hz, 3H, CH3); 13C 
NMR (75 MHz, CDCl3): δ 167.0, 165.4, 135.8, 126.5, 
122.7, 122.1, 119.5, 118.3, 111.0, 108.1, 31.6, 28.8, 
26.1, 25.0, 22.4, 21.8, 13.8; IR (CHCl3 νmax cm-1): 
3442, 3015, 2960, 2937, 1574, 1499, 1464, 1419, 
1217, 1130, 1002, 755, 666; MS (ESI, m/z) [M+H]+ 
410; HR-MS (ESI) m/z [M+H+]: calc for C26H40ON3 
is 410.31659 found 410.31581 (C26H40ON3). 
 
2-((1H-Indol-3-yl) methyl)-5-heptadecyl-1,3,4-
oxadiazole, 4i 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 58% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.18 (s, 1H, 
NH), 7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.38 (d, J = 
7.9Hz, 1H, Ar-H), 7.11-7.23 (m, 3H, Ar-H), 4.31  
(s, 2H, CH2), 2.73-2.77 (t, J = 7.5Hz, 2H, CH2), 1.68-
1.75 (t, J =7.4Hz, 2H, CH2), 1.23-1.33 (m, 28H,  
(-CH2-)14), 0.86 – 0.89 (t, J = 6.7Hz, 3H, CH3); 13C 
NMR (75 MHz, CDCl3): δ 167.3, 165.6, 136.1, 126.7, 
122.9, 122.4, 119.8, 118.6, 111.2, 108.4, 31.8, 29.6, 
28.9, 26.3, 25.3, 22.6, 22.0, 14.1; IR (CHCl3 νmax cm-
1): 3449, 3015, 2936, 1574, 14989, 1463, 1419, 1217, 
1130, 755, 666; MS (ESI, m/z) [M+Na]+ 460; HR-MS 
(ESI) m/z [M+H+]: calc for C28H44ON3 is 438.34789 
found 438.34713 (C28H44ON3). 
 
2-((1H-Indol-3-yl) methyl)-5-(heptadec-8-en-1-yl)-
1,3,4-oxadiazole, 4j 
The title compound was obtained in hexane: ethyl 
acetate (60: 40, v/v) solvent with 52% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 8.22 (s, 1H, NH), 
7.62 (d, J = 7.9Hz, 1H, Ar-H), 7.36 (d, J = 7.9Hz, 1H, 
Ar-H), 7.11-7.23 (m, 3H, Ar-H), 5.33-5.38 (m, 2H, -
CH= CH-),4.31 (s, 2H, CH2), 2.73-2.77 (t, J = 7.5Hz, 
2H, CH2), 1.93-2.04 (m, 4H, -CH2-CH= CH-CH2-), 
1.68-1.75 (t, J =7.4Hz, 2H, CH2), 1.25-1.31 (m, 20H, (-
CH2-)10), 0.85 – 0.89 (t, J = 6.7Hz, 3H, CH3); 13C NMR 
(75 MHz, CDCl3): δ 167.0, 165.4, 135.9, 130.0, 126.4, 
122.7, 122.0, 119.4, 118.2, 111.0, 107.9, 32.2, 31.5, 
29.3, 28.6, 26.9, 25.0, 22.3, 14.1; IR (CHCl3 νmax cm-1): 
3272, 2922, 2851, 1722, 1599, 1567, 1463, 1164, 1105, 
965, 741; MS (ESI, m/z) [M+Na]+ 458; HR-MS (ESI) 
m/z [M+H+]: calc for C28H42ON3 is 436.33224 found 
436.33150 (C28H42ON3). 
 
Synthesis of ethyl 3,4,5-trimethoxybenzoate, 6 
The ester was prepared by refluxing 3,4,5-
trimethoxybenzoic acid (5 g, 1 mmol) in excess of 
absolute ethanol (50 mL) in the presence of a few drops 
of conc. sulphuric acid for 12 h and the progress of 
reaction was monitored by TLC. After 12 h reaction 
time, the solvent was evaporated under reduced 
pressure, water was added and the product was extracted 
with ethyl acetate and dried over anhydrous sodium 
sulphate. The crude product was purified by using 
column chromatography to afford the title compound in 
86% yield. 1H NMR (300 MHz, CDCl3): δ 7.30 (s, 2H, 
Ar-H), 4.39-4.37 (m, 2H, CH2), 3.91 (s, 6H, OCH3), 
3.90 (s, 3H, OCH3), 1.38-1.41 (t, J = 7.1Hz, 3H, CH3); 
MS (ESI, m/z) [M+Na]+ 263. 
 
Synthesis of 3,4,5-trimethoxybenzohydrazide, 7 
A mixture of ethyl 3,4,5-trimethoxybenzoate (2 g, 
1 mmol), hydrazine hydrate (6 mL, 15 mmol) and 20 
mL of ethanol was refluxed on an oil bath for 10 h 
and the progress of reaction was monitored by TLC. 
After 10 h reaction time, the solvent was evaporated 
under reduced pressure and the concentrated solution 
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was quenched to ice cold water. The solid separated 
was filtered, washed and dried. The crude product 
was purified by recrystalization from ethanol, which 
afforded the title compound in 74% yield. 1H NMR 
(300 MHz, CDCl3): δ 7.53 (Broad-singlet, 1H, NH), 
6.98 (s, 2H, Ar-H), 4.12 (Broad-singlet, 2H, NH2), 
3.89 (s, 6H, OCH3), 3.88 (s, 3H, OCH3); MS (ESI, 
m/z) [M+Na]+ 249. 
 
General procedure for the synthesis of target 
compounds, 8a-j 
A mixture of 3,4,5-trimethoxybenzohydrazide (7) 
(1mmol), fatty acids (1mmol) and phosphorous 
oxychloride (2.5mL) was refluxed for 6 h. The excess 
solvent was distilled off under reduced pressure and 
the residue was quenched with ice cold water and the 
product was extracted with ethyl acetate and dried 
over anhydrous sodium sulphate. The crude product 
was purified by using column chromatography by 
eluting with ethyl acetate: hexane (30:70 v/v), which 
afforded the title compound in 81-87% yield. 
 
2-Propyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-
oxadiazole, 8a 
The title compound was obtained in hexane: ethyl 
acetate (55: 45, v/v) solvent with 48% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.89-2.92 
(t, J = 7.4Hz, 2H, CH2), 1.86-1.92 (m, 2H, CH2), 
1.05-1.09 (t, J = 6.8Hz, 3H, CH3); 13C NMR (75 
MHz, CDCl3): δ 166.4, 164.2, 153.2, 140.5, 118.8, 
103.6, 60.6, 56.0, 26.9, 19.8, 13.2; IR (CHCl3 νmax cm-
1): 3416, 3253, 2927, 2864, 1594, 1458, 1107, 753, 
666; MS (ESI, m/z) [M+Na]+ 301; HR-MS (ESI) m/z 
[M+H+]: calc for C14H19O4N2 is 279.13393 found 
279.13324 (C14H19O4N2). 
 
2-Pentyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole, 
8b 
The title compound was obtained in hexane: ethyl 
acetate (55: 45, v/v) solvent with 54% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.90-2.94 
(t, J = 7.4Hz, 2H, CH2), 1.82-1.88 (m, 2H, CH2), 
1.38-1.44 (m, 4H, (-CH2-)2), 0.91-0.94 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 166.9, 
164.5, 153.5, 140.7, 119.1, 103.9, 60.9, 56.3, 31.2, 
26.2, 25.3, 22.1, 13.8; IR (CHCl3 νmax cm-1): 3416, 
3253, 2927, 2864, 1594, 1458, 1107, 753, 666; MS 
(ESI, m/z) [M+Na]+ 329; HR-MS (ESI) m/z [M+H+]: 
calc for C16H23O4N2 is 307.16523 found 307.16443 
(C16H23O4N2). 
2-Heptyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole, 
8c 
The title compound was obtained in hexane: ethyl 
acetate (55: 45, v/v) solvent with 60% yield as a 
liquid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, 
Ar-H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.90-
2.94 (t, J = 7.4Hz, 2H, CH2), 1.81-1.89 (m, 2H, CH2), 
1.25-1.35 (m, 8H, (-CH2-)4), 0.87-0.90 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 167.2, 
164.8, 153.9, 141.1, 119.5, 104.2, 61.2, 56.6, 31.9, 
29.0, 26.9, 25.7, 22.8, 14.3; IR (CHCl3 νmax cm-1): 
3416, 3251, 2925, 2865, 1646, 1596, 1568, 1425, 
1394, 1166, 1125, 1107, 740; MS (ESI, m/z) [M+H]+ 
335; HR-MS (ESI) m/z [M+H+]: calc for C18H27O4N2 
is 335.19653 found 335.19579 (C18H27O4N2). 
 
2-Nonyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadiazole, 
8d 
The title compound was obtained in hexane: ethyl 
acetate (55: 45, v/v) solvent with 63% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.90-2.93 
(t, J = 7.4Hz, 2H, CH2), 1.81-1.88 (m, 2H, CH2), 
1.25-1.35 (m, 12H, (-CH2-)6), 0.86-0.89 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 167.2, 
164.8, 153.9, 141.1, 119.5, 104.2, 61.2, 56.6, 32.1, 
29.3, 26.9, 25.7, 22.9, 14.4; IR (CHCl3 νmax cm-1): 
3416, 3250, 2924, 2865, 1640, 1596, 1425, 1107, 739, 
714; MS (ESI, m/z) [M+H]+ 363; HR-MS (ESI) m/z 
[M+H+]: calc for C20H31O4N2 is 363.22783 found 
363.22720 (C20H31O4N2). 
 
2-(Dec-9-en-1-yl)-5-(3,4,5-trimethoxyphenyl)-1,3,4-
oxadiazole, 8e 
The title compound was obtained in hexane: ethyl 
acetate (55: 45, v/v) solvent with 68% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 5.37-5.42 (m, 1H, CH2-CH=CH2), 4.08-4.14 (m, 
2H, CH2-CH=CH2), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, 
OCH3),2.90-2.93 (t, J = 7.4Hz, 2H, CH2), 1.94-2.01 
(m, 2H, CH2),1.81-1.87 (m, 2H, CH2), 1.28-1.39 (m, 
10H, (-CH2-)5); 13C NMR (75 MHz, CDCl3): δ 166.6, 
164.2, 153.3, 140.5, 131.8, 124.3, 103.6, 60.6, 56.0, 
31.9, 28.6, 26.2, 25.1, 22.3, 17.5, 13.3; IR (CHCl3 νmax 
cm-1): 2930, 2853, 1727, 1573, 1497, 1419, 1237, 
1129, 1005, 770; MS (ESI, m/z) [M+H]+ 375; HR-MS 
(ESI) m/z [M+H+]: calc for C21H31O4N2 is 375.22783 
found 375.22735 (C21H31O4N2). 
 
2-(3,4,5-Trimethoxyphenyl)-5-undecyl-1,3,4-
oxadiazole, 8f 
The title compound was obtained in hexane: ethyl 
acetate (55: 45, v/v) solvent with 65% yield as a semi 
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solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.90-2.93 
(t, J = 7.4Hz, 2H, CH2), 1.81-1.88 (m, 2H, CH2), 
1.25-1.35 (m, 16H, (-CH2-)8), 0.86-0.89 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 165.3, 
162.7, 152.0, 139.1, 117.5, 102.3, 59.1, 54.7, 30.2, 
27.8, 24.9, 23.7, 20.9, 12.5; IR (CHCl3 νmax cm-1): 
2920, 2850, 1727, 1574, 1499, 1417, 1236, 1128, 991, 
729; MS (ESI, m/z) [M+H]+ 391; HR-MS (ESI) m/z 
[M+H+]: calc for C22H35O4N2 is 391.25913 found 
391.25870 (C22H35O4N2). 
 
2-Tridecyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-
oxadiazole, 8g 
The title compound was obtained in hexane: ethyl 
acetate (45: 55, v/v) solvent with 67% yield as a 
liquid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, 
Ar-H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3),2.90-
2.94 (t, J = 7.4Hz, 2H, CH2), 1.82-1.88 (m, 2H, CH2), 
1.25-1.35 (m, 20H, (-CH2-)10), 0.86-0.89 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 167.2, 
164.8, 153.8, 141.1, 119.4, 104.2, 61.2, 56.6, 32.1, 
29.8, 26.9, 25.7, 22.9, 14.3; IR (CHCl3 νmax cm-1): 
3416, 3250, 2924, 2865, 1568, 1425, 1108, 739, 714; 
MS (ESI, m/z) [M+H]+ 419; HR-MS (ESI) m/z 
[M+H+]: calc for C24H39O4N2 is 419.29043 found 
419.28947 (C24H39O4N2). 
 
2-Pentadecyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxadi 
azole, 8h 
The title compound was obtained in hexane: ethyl 
acetate (45: 55, v/v) solvent with 62% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.90-2.93 
(t, J = 7.4Hz, 2H, CH2), 1.81-1.88 (m, 2H, CH2), 
1.25-1.35 (m, 24H, (-CH2-)12), 0.86-0.89 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 166.9, 
164.5, 153.5, 140.8, 119.1, 103.9, 60.9, 56.3, 31.8, 
29.6, 26.6, 25.4, 22.6, 14.0; IR (CHCl3 νmax cm-1): 
3416, 3250, 2946, 2924, 2865, 1596, 1569, 1425, 
1108, 739, 714; MS (ESI, m/z) [M+H]+ 447; HR-MS 
(ESI) m/z [M+H+]: calc for C26H43O4N2 is 447.32173 
found 447.32075 (C26H43O4N2). 
 
2-Heptadecyl-5-(3,4,5-trimethoxyphenyl)-1,3,4-oxa 
diazole, 8i 
The title compound was obtained in hexane: ethyl 
acetate (45: 55, v/v) solvent with 69% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 3.91 (s, 6H, OCH3), 3.94 (s, 3H, OCH3), 2.90-2.93 
(t, J = 7.4Hz, 2H, CH2), 1.81-1.88 (m, 2H, CH2), 
1.25-1.31 (m, 28H, (-CH2-)14), 0.86-0.89 (t, J = 6.8Hz, 
3H, CH3); 13C NMR (75 MHz, CDCl3): δ 167.1, 
164.7, 153.8, 141.1, 119.4, 104.2, 61.2, 56.5, 32.1, 
29.9, 26.8, 25.7, 22.9, 14.3; IR (CHCl3 νmax cm-1): 
3416, 3250, 2924, 2865, 1709, 1597, 1569, 1425, 
1125, 1108, 739; MS (ESI, m/z) [M+H]+ 475; HR-MS 
(ESI) m/z [M+H+]: calc for C28H47O4N2 is 475.35303 
found 475.35211 (C28H47O4N2). 
 
2-(Heptadec-8-en-1-yl)-5-(3,4,5-trimethoxyphenyl)-
1,3,4-oxadiazole, 8j 
The title compound was obtained in hexane: ethyl 
acetate (45: 55, v/v) solvent with 63% yield as a semi 
solid. 1H NMR (300 MHz, CDCl3): δ 7.26 (s, 2H, Ar-
H), 5.34-5.41 (m, 2H, -CH= CH-), 3.91 (s, 6H, 
OCH3), 3.94 (s, 3H, OCH3), 2.89-2.93 (t, J = 7.4Hz, 
2H, CH2), 1.94-2.00 (m, 4H, -CH2-CH= CH-CH2-), 
1.81-1.88 (m, 2H, CH2), 1.25-1.36 (m, 4H, (-CH2-)2), 
0.86-0.89 (t, J = 6.8Hz, 3H, CH3); 13C NMR  
(75 MHz, CDCl3): δ 167.2, 164.8, 153.9, 141.1, 
130.3, 119.4, 104.2, 61.2, 56.6, 32.8, 32.1, 29.9, 29.3, 
26.9, 25.7, 22.9, 14.3; IR (CHCl3 νmax cm-1): 3250, 
2946, 2924, 2865, 1710, 1569, 1425, 1166, 1108, 739, 
713; MS (ESI, m/z) [M+H]+ 473; HR-MS (ESI) m/z 
[M+H+]: calc for C28H45O4N2 is 473.33738 found 
473.33678 (C28H45O4N2). 
 
Biological evaluation 
All the synthesized compounds were screened for 
in vitro cytotoxicity on a panel of three different 
cancer cell lines such as A549 derived from human 
alveolar adenocarcinoma epithelial cells (ATCC No. 
CCL-185), HeLa derived from human 
adenocarcinoma cells (ATCC No. CCL-185) and 
MCF7 derived from human breast adenocarcinoma 
cells (ATCC No HTB-22), which were all obtained 
from the American Type Culture Collection, 
Manassas, VA, USA. The cytotoxicity was 
determined using MTT 35.The effects of the different 
synthesized compounds on the viability of the tumour 
cell lines were measured at 540 nm using a multimode 
reader (Infinite® M200, Tecan, Switzerland). The IC50 
values (50% inhibitory concentration) were calculated 
from the plotted absorbance data of the dose–response 
curves. The assay was performed using doxorubicin 
as positive controls and 1% DMSO as a vehicle 
control. In order to account for the toxicity of DMSO, 
the values obtained for the DMSO control were 
subtracted from those of the test compounds. The IC50 
values (in mM) are expressed as the average of two 
independent experiments. 
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Conclusions 
In conclusion, we have efficiently synthesized two 
series of 1,3,4-oxadiazole derivatives through simple 
steps. All the synthesized compounds were evaluated for 
their cytotoxicity. Antitumor evaluation showed that 
almost all the tested compounds revealed activity. It is 
interesting to note that the substitution of heteryl and fatty 
chain groups on 1,3,4-oxadiazoles-based compounds (4c, 
4d, 4e) displayed the most potent inhibitory activity when 
compared to aryl and fatty chain groups on 1,3,4-
oxadiazoles. 
 
Supplementary Information 
Supplementary information is available in the website 
http://nopr.niscair.res.in/handle/123456789/60. 
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